UA42684C2 - Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі - Google Patents

Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі

Info

Publication number
UA42684C2
UA42684C2 UA94005462A UA94005462A UA42684C2 UA 42684 C2 UA42684 C2 UA 42684C2 UA 94005462 A UA94005462 A UA 94005462A UA 94005462 A UA94005462 A UA 94005462A UA 42684 C2 UA42684 C2 UA 42684C2
Authority
UA
Ukraine
Prior art keywords
acid addition
addition salts
alkyl
physiologically acceptable
acceptable acid
Prior art date
Application number
UA94005462A
Other languages
English (en)
Russian (ru)
Inventor
Джузеппе Бієтті
Джузеппе Биетти
Франко Борсіні
Франко Борсини
Марко Турконі
Марко Туркони
Етторе Джіральдо
Этторе Джиральдо
Маура Бігнотті
Маура Бигнотти
Original Assignee
Берінгер Інгельхейм Італія С.П.А.
Берингер Ингельхейм Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берінгер Інгельхейм Італія С.П.А., Берингер Ингельхейм Италия С.П.А. filed Critical Берінгер Інгельхейм Італія С.П.А.
Publication of UA42684C2 publication Critical patent/UA42684C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Метою винаходу є розширення асортименту похідних бензимідазолону, що є, зокрема, антагоністом рецептора 5-НТ1A і 5-НT2. Поставлена мета досягається пропонованими похідними бензимідазолону загальної формули (I) (І) де R1 і R2 однакові або різні й означають атом водню, атом галогену, алкіл з 1-6 атомами вуглецю, алкокси з 1-6 атомами вуглецю, R3 - атом водню, алкіл з 1-6 атомами вуглецю, алкеніл з 2-6 атомами вуглецю, А - група -СО- або -CONH-, або ж А відсутня, В - нерозгалужений насичений алкіл з 2-6 атомами вуглецю, R4 - феніл, нафтил, незаміщеним або заміщені щонайменше одним заступником із групи, що включає атом фтору або хлору, трифторметил, метокси, етокси, метил, етил, або бензодиоксан, m і n кожне означає число 2, та їх фізіологічно прийнятні кислотно-адитивні солі.
UA94005462A 1991-07-30 1992-07-30 Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі UA42684C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI912118A IT1251144B (it) 1991-07-30 1991-07-30 Derivati del benzimidazolone
PCT/IT1992/000088 WO1993003016A1 (en) 1991-07-30 1992-07-30 Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists

Publications (1)

Publication Number Publication Date
UA42684C2 true UA42684C2 (uk) 2001-11-15

Family

ID=11360463

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94005462A UA42684C2 (uk) 1991-07-30 1992-07-30 Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі

Country Status (32)

Country Link
US (1) US5576318A (uk)
EP (1) EP0526434B1 (uk)
JP (1) JP2989667B2 (uk)
KR (1) KR100263495B1 (uk)
AT (1) ATE191910T1 (uk)
AU (1) AU665366B2 (uk)
CA (1) CA2114542C (uk)
CZ (1) CZ281511B6 (uk)
DE (1) DE69230926T2 (uk)
DK (1) DK0526434T3 (uk)
EE (1) EE03070B1 (uk)
ES (1) ES2144412T3 (uk)
FI (1) FI111460B (uk)
GR (1) GR3033947T3 (uk)
HK (1) HK1010725A1 (uk)
HU (2) HUT70195A (uk)
IE (1) IE922464A1 (uk)
IL (1) IL102665A (uk)
IT (1) IT1251144B (uk)
MX (1) MX9204139A (uk)
NO (1) NO304070B1 (uk)
NZ (1) NZ243777A (uk)
PH (1) PH30998A (uk)
PL (1) PL171329B1 (uk)
PT (1) PT526434E (uk)
RU (1) RU2096411C1 (uk)
SG (1) SG52407A1 (uk)
SK (1) SK279292B6 (uk)
TW (1) TW209862B (uk)
UA (1) UA42684C2 (uk)
WO (1) WO1993003016A1 (uk)
ZA (1) ZA925682B (uk)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
SE9201138D0 (sv) * 1992-04-09 1992-04-09 Astra Ab Novel phthalimidoalkylpiperazines
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
DE69427289T2 (de) * 1993-03-16 2001-09-06 Pfizer Inc., New York Naphtalinderivate
JP3719612B2 (ja) * 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体
IL114027A (en) * 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
WO1995034555A1 (en) * 1994-06-14 1995-12-21 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
CA2196769C (en) * 1994-08-05 2002-10-08 William S. Faraci Benzimidazole derivatives having dopaminergic activity
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5889010A (en) * 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
AU7478496A (en) * 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
EP1087954A1 (en) * 1998-06-15 2001-04-04 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
DE60123643T2 (de) * 2000-09-19 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
EP1322622B1 (en) * 2000-09-19 2012-10-31 Sprout Pharmaceuticals, Inc. New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
EP1408976B3 (en) * 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
EP1414816B1 (en) * 2001-08-02 2005-02-09 BIDACHEM S.p.A. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
RS51718B (en) * 2002-05-22 2011-10-31 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERINE POLYMORF A
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
BR0314393A (pt) * 2002-09-17 2005-07-19 Warner Lambert Co Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
ATE539077T1 (de) * 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2005102342A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
MXPA06014486A (es) * 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Method for the treatment of attention deficit hyperactivity disorder
AP2007004067A0 (en) * 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090176698A1 (en) * 2006-02-20 2009-07-09 Boehringer Ingelheim International Gmbh Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
EP1988077A4 (en) * 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
EP1991228A1 (en) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
ES2336719T3 (es) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas.
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
WO2008019996A2 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
JP5514716B2 (ja) * 2007-05-11 2014-06-04 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009092720A1 (en) * 2008-01-24 2009-07-30 Neurosearch A/S 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010146595A2 (en) * 2009-06-16 2010-12-23 Symed Labs Limited Novel polymorphs of flibanserin hydrochloride
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a
CA2885476A1 (en) * 2012-10-11 2014-04-17 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076213A1 (zh) * 2015-11-02 2017-05-11 苏州旺山旺水生物医药有限公司 苯并咪唑类化合物、其制备方法及用途
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN106749038A (zh) * 2015-11-25 2017-05-31 山东诚创医药技术开发有限公司 一种氟班色林的制备方法
CN106866546A (zh) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
US11492343B2 (en) 2016-01-31 2022-11-08 Xiaoming Meng Polymorph of flibanserin and preparation method thereof and use of same
CN108349908B (zh) * 2016-02-02 2021-07-20 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物
CN107235913B (zh) * 2016-03-29 2020-07-10 苏州科伦药物研究有限公司 工业规模高效制造优质氟班色林的方法
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
HU231283B1 (hu) 2018-08-01 2022-09-28 Richter Gedeon Nyrt Eljárás a flibanserin többlépéses folyamatos áramú előállítására
US20240199555A1 (en) * 2021-03-19 2024-06-20 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
YU39992B (en) * 1976-04-02 1985-06-30 Janssen Pharmaceutica Nv Process for obtaining new piperazine and piperidine derivatives
IL57569A0 (en) * 1978-06-20 1979-10-31 Synthelabo Phenylpiperazine derivative,their preparation and pharmaceutical compositions containing them
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
IE922464A1 (en) 1993-02-10
PH30998A (en) 1997-12-23
IT1251144B (it) 1995-05-04
US5576318A (en) 1996-11-19
CZ281511B6 (cs) 1996-10-16
NO304070B1 (no) 1998-10-19
NZ243777A (en) 1995-04-27
DE69230926D1 (de) 2000-05-25
AU665366B2 (en) 1996-01-04
MX9204139A (es) 1993-01-01
KR100263495B1 (ko) 2000-11-01
SG52407A1 (en) 1998-09-28
DK0526434T3 (da) 2000-07-17
ITMI912118A0 (it) 1991-07-30
GR3033947T3 (en) 2000-11-30
JP2989667B2 (ja) 1999-12-13
RU2096411C1 (ru) 1997-11-20
FI940420A0 (fi) 1994-01-28
EE03070B1 (et) 1998-02-16
PL171329B1 (pl) 1997-04-30
HUT70195A (en) 1995-09-28
DE69230926T2 (de) 2000-10-05
ATE191910T1 (de) 2000-05-15
ES2144412T3 (es) 2000-06-16
TW209862B (uk) 1993-07-21
ITMI912118A1 (it) 1993-01-31
FI111460B (fi) 2003-07-31
SK279292B6 (sk) 1998-09-09
ZA925682B (en) 1994-01-31
EP0526434B1 (en) 2000-04-19
AU2427592A (en) 1993-03-02
HK1010725A1 (en) 1999-06-25
CA2114542A1 (en) 1993-02-18
PL302163A1 (en) 1994-07-11
NO940306D0 (no) 1994-01-28
HU211256A9 (en) 1995-11-28
IL102665A (en) 1996-10-31
CA2114542C (en) 2004-02-24
EP0526434A1 (en) 1993-02-03
HU9400255D0 (en) 1994-05-30
WO1993003016A1 (en) 1993-02-18
SK10194A3 (en) 1994-12-07
PT526434E (pt) 2000-08-31
NO940306L (no) 1994-03-14
JPH06509575A (ja) 1994-10-27
CZ17094A3 (en) 1994-05-18
FI940420A (fi) 1994-01-28

Similar Documents

Publication Publication Date Title
UA42684C2 (uk) Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі
ES8704926A1 (es) Un procedimiento para la preparacion de derivados de benzotiazol y benzotiofeno
HK1034707A1 (en) Heterocyclic compounds and methods to treat cardiac failure and other disorders
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
ES530902A0 (es) Procedimiento para preparar derivados de piperazina
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
FI964815A (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
FI942635A (fi) Piperatsiinijohdannaiset 5HT1A-antagonisteina
DE69529418D1 (de) Cyclopropachromencarbonsäure derivate
ES8203845A1 (es) Procedimiento para preparar derivados de piridoxina
ATE175661T1 (de) Benzamid-derivate als vasopressin-antagonisten
ES8800122A1 (es) Un procedimiento para la preparacion de derivados de indeno y naftaleno.
ZA831477B (en) Substituted pyridines,processes for preparing these and pharmaceutical composition thereof
SE8901060D0 (sv) New compounds
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
MY104630A (en) 4(1h) ouinoline derivatives
ES2056025A1 (es) Nuevos derivados de indol.
YU38498A (sh) Derivati 2-(arilfenil)amino-imidazolina
TH17157A (th) อนุพันธ์ไพริมิดีนอะไซโคลนิวคลีโอไซด์
MY104554A (en) Benzofuran derivatives.